Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Business Insider1d
Bristol Myers Squibb put volume heavy and directionally bearish
Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...
MarketWatch2d
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...
Bristol Myers price target raised to $61 from $57 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Hosted on MSN2d
Bristol Myers Squibb Gets RS Rating Upgrade
Bristol Myers Squibb had its Relative Strength (RS) Rating upgraded from 63 to 79 Tuesday — a welcome improvement, but still ...
pharmaphorum3d
Autolus bags FDA approval for leukaemia cell therapy
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...
Barron's4d
Bristol Myers Squibb Co.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...